R21/Matrix-M malaria vaccine demonstrated 74% efficacy against severe malaria in a Phase III trial of 4,800 children across four African countries. The booster shot provides protection for at least 2 years.
74% % Vaccine efficacy
4,800 children Children in trial
2 Years years Protection duration
4 African Countries countries Trial countries